Date: 2014-12-08
Type of information: Fundraising
Company: Quantum Genomics (France)
Investors:
Amount: € 3 million
Funding type: fundraising
Planned used: These funds strengthen the cash position of the company at a time when Quantum Genomics is very close to launch its phase II clinical trials of QGC001, first in class drug candidate for the treatment of hypertension.
Others: * On December 8, 2014, Quantum Genomics, a biopharmaceutical company with the mission of developing new therapies for unmet medical needs in the field of cardiovascular diseases, announced that it received a medium-term financing of 3 M€, through a bond issue. This strengthens the cash position of the company at a time when Quantum Genomics is very close to launch its phase II clinical trials of QGC001, first in class drug candidate for the treatment of hypertension.
Therapeutic area: Cardiovascular diseases
